Get the Stockscreener App
1.27
4.51%
-0.06
After Hours:
1.33
0.06
+4.72%
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology Inc [PYXS] Investment Guide: What You Need to Know - Knox Daily
Financial Health Report: Pyxis Oncology Inc (PYXS)’s Ratios Tell a Tale - The Dwinnex
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts - Armenian Reporter
Pyxis Oncology Inc (PYXS) Beta Value: Understanding the Market Risk - The News Heater
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
A year in review: Pyxis Oncology Inc (PYXS)’s performance in the last year - US Post News
Financial Metrics Unveiled: Pyxis Oncology Inc (PYXS)’s Key Ratios in the Spotlight - The Dwinnex
BlackRock, Inc. Increases Stake in Pyxis Oncology Inc - GuruFocus.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - Marketscreener.com
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of ... - The Bakersfield Californian
Major Clinical Advance: Pyxis Teams with Merck for Groundbreaking Cancer Therapy Trial - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Holdings Raised by Jane Street Group LLC - Defense World
Pyxis Oncology stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.49 - Investing.com India
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Average Price Target from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC - Defense World
Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pick Pyxis in head and neck despite pullback on ADC phase I? - BioWorld Online
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management - Investing.com Nigeria
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management By Investing.com - Investing.com South Africa
Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology advances lead cancer drug PYX-201 By Investing.com - Investing.com Canada
Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program - MarketWatch
Pyxis Oncology advances lead cancer drug PYX-201 - Investing.com
Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106 - TipRanks
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Manila Times
Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201 - Marketscreener.com
Pyxis Oncology stock hits 52-week low at $1.5 amid market challenges - Investing.com Canada
Pyxis Oncology's SWOT analysis: ADC developer's stock shows promise amid trials - Investing.com Canada
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Average Price Target from Brokerages - MarketBeat
Pyxis Oncology stock hits 52-week low at $1.64 - Investing.com
Pyxis Oncology stock hits 52-week low at $1.64 By Investing.com - Investing.com UK
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):